• Policy
• What's patient-centered safety in the biopharmaceutical era?
• by Lee, Hye-Kyung Sep 7, 2022 05:52am

• Company
• Godex’s price to be cut further under PVA
• by Nho, Byung Chul Sep 7, 2022 05:52am

• Company
• Poziotinib responds 100% to pts with lung cancer mutations
• by Sep 7, 2022 05:52am

• Policy
• Antiemetic Emend's generic benefit after 15 yrs since origin
• by Lee, Tak-Sun Sep 7, 2022 05:51am

• Policy
• Enactment of preferential pricing sublaws slow
• by Lee, Jeong-Hwan Sep 6, 2022 05:51am

• Policy
• The goal shorten the development of mRNA vaccine to 100 days
• by Lee, Hye-Kyung Sep 6, 2022 05:51am

• Company
• Kisqali’s sales surge, Ibrance’s sales falter
• by Sep 6, 2022 05:51am

• Policy
• Checking the effectiveness of SKYCovione,
• by Kim, Jung-Ju Sep 6, 2022 05:51am

• Policy
• Including SKYCovione, 6 types of COVID-19 vaccines
• by Lee, Jeong-Hwan Sep 6, 2022 05:51am

• Company
• Prevenar 13 set to make ₩40B this year
• by Nho, Byung Chul Sep 5, 2022 05:55am